Goldberg Andrew D. 4

What Happened

• Andrew D. Goldberg, a non‑employee director of Tarsus Pharmaceuticals (TARS), received two awards on June 25, 2026: a grant of 3,837 derivative shares (stock options) and 2,417 Restricted Stock Units (RSUs). Both grants were recorded at $0.00 (no cash paid). These are awards/compensation grants, not open‑market purchases or sales.

Key Details

• Transaction date: 2026-06-25; Filing date: 2026-06-29.
• Grants: 3,837 options (derivative) @ $0.00; 2,417 RSUs @ $0.00.
• Vesting: Options vest in full on the one‑year anniversary of grant (F1). RSUs convert to one share each and vest in full on the one‑year anniversary of grant (F2, F3), subject to continuous service.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Filing timeliness: Form 4 was filed June 29, 2026. For a June 25 transaction this filing date is within the typical two‑business‑day Form 4 reporting window (i.e., appears timely).
• Nature of transaction: Award/Grant (code A); both entries are derivative/contingent (options and RSUs).

Context

• The options were granted (not exercised), and the RSUs are a contingent right to receive shares on vesting — neither transaction resulted in immediate share sales or purchases in the open market. These types of grants are common director compensation and should be viewed as compensation awards rather than a direct bullish or bearish insider market signal.